1. Market Research
  2. > Biotechnology Market Trends
  3. > Mycenax Biotech Inc. - Product Pipeline Review - 2013

Mycenax Biotech Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 23 pages

Mycenax Biotech Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Mycenax Biotech Inc. - Product Pipeline Review - 2013” provides data on the Mycenax Biotech Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mycenax Biotech Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Mycenax Biotech Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Mycenax Biotech Inc. - Brief Mycenax Biotech Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mycenax Biotech Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mycenax Biotech Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mycenax Biotech Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mycenax Biotech Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mycenax Biotech Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mycenax Biotech Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mycenax Biotech Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mycenax Biotech Inc. and identify potential opportunities in those areas.

Table Of Contents

Mycenax Biotech Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Mycenax Biotech Inc. Snapshot 4
Mycenax Biotech Inc. Overview 4
Key Information 4
Key Facts 4
Mycenax Biotech Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Mycenax Biotech Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Mycenax Biotech Inc. - Pipeline Products Glance 9
Mycenax Biotech Inc. - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Mycenax Biotech Inc. - Early Stage Pipeline Products 10
IND/CTA Filed Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Mycenax Biotech Inc. - Drug Profiles 12
etanercept biosimilar 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
filgrastim biosimilar 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
CX-99 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Mycenax Biotech Inc. - Pipeline Analysis 15
Mycenax Biotech Inc. - Pipeline Products by Therapeutic Class 15
Mycenax Biotech Inc. - Pipeline Products by Target 16
Mycenax Biotech Inc. - Pipeline Products by Route of Administration 17
Mycenax Biotech Inc. - Pipeline Products by Molecule Type 18
Mycenax Biotech Inc. - Pipeline Products by Mechanism of Action 19
Mycenax Biotech Inc. - Dormant Projects 20
Mycenax Biotech Inc. - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23



List of Tables

Mycenax Biotech Inc., Key Information 4
Mycenax Biotech Inc., Key Facts 4
Mycenax Biotech Inc. - Pipeline by Indication, 2013 6
Mycenax Biotech Inc. - Pipeline by Stage of Development, 2013 7
Mycenax Biotech Inc. - Monotherapy Products in Pipeline, 2013 8
Mycenax Biotech Inc. - Phase III, 2013 9
Mycenax Biotech Inc. - IND/CTA Filed, 2013 10
Mycenax Biotech Inc. - Discovery, 2013 11
Mycenax Biotech Inc. - Pipeline by Therapeutic Class, 2013 15
Mycenax Biotech Inc. - Pipeline by Target, 2013 16
Mycenax Biotech Inc. - Pipeline by Route of Administration, 2013 17
Mycenax Biotech Inc. - Pipeline by Molecule Type, 2013 18
Mycenax Biotech Inc. - Pipeline Products by Mechanism of Action, 2013 19
Mycenax Biotech Inc. - Dormant Developmental Projects,2013 20



List of Figures

Mycenax Biotech Inc. - Pipeline by Top 10 Indication, 2013 6
Mycenax Biotech Inc. - Pipeline by Stage of Development, 2013 7
Mycenax Biotech Inc. - Monotherapy Products in Pipeline, 2013 8
Mycenax Biotech Inc. - Pipeline by Top 10 Therapeutic Class, 2013 15
Mycenax Biotech Inc. - Pipeline by Top 10 Target, 2013 16
Mycenax Biotech Inc. - Pipeline by Top 10 Route of Administration, 2013 17
Mycenax Biotech Inc. - Pipeline by Top 10 Molecule Type, 2013 18
Mycenax Biotech Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013 19



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Telomerase ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.